Research programme: TNF antagonists - Xencor

Drug Profile

Research programme: TNF antagonists - Xencor

Alternative Names: TNF monoclonal antibodies - Xencor; Tumour necrosis factor antagonists - Xencor; XmAb 6755; Xtend-TNF

Latest Information Update: 26 Jul 2016

Price : $50

At a glance

  • Originator Xencor
  • Class Monoclonal antibodies; Proteins; Tumour necrosis factors
  • Mechanism of Action RANK ligand inhibitors; Tumour necrosis factor alpha inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Bone disorders
  • Discontinued Inflammation

Most Recent Events

  • 11 Apr 2014 A biosuperior anti-TNF, Xtend-TNF, monoclonal antibody is still in preclinical trials for Autoimmune disorders in USA (Xencor's pipeline)
  • 23 Feb 2012 A biosuperior anti-TNF monoclonal antibody is in preclinical development for Autoimmune disorders in USA
  • 29 Nov 2006 Data presented at the 70th Annual Scientific Meeting of the American College of Rheumatology (ACR-2006) have been added to the Rheumatic Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top